C4 Therapeutics, Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics, Inc
NASDAQ:CCCC
|
US |
|
H
|
Helmerich and Payne Inc
XMUN:HPC
|
US |
|
B
|
Bumi Resources Minerals Tbk PT
XMUN:BUR
|
ID |
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
|
S
|
SoftBank Group Corp
DUS:SFT
|
JP |
|
Duxton Farms Ltd
ASX:DBF
|
AU |
|
T
|
Thermo Fisher Scientific Inc
XMUN:TN8
|
US |
|
V
|
Vinci SA
XHAN:SQU
|
FR |
Intrinsic Value
Is CCCC undervalued or overvalued?
See the intrinsic value estimate for
C4 Therapeutics, Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What C4 Therapeutics Does
C4 Therapeutics is a drug-development company focused on targeted protein degradation. Instead of trying to block a disease-causing protein, it designs small-molecule medicines that tag that protein for removal by the cell’s own cleanup system. Its main work is in oncology, where it builds drug candidates aimed at cancers driven by hard-to-treat proteins.
- Headquarters
- United States of America US
- Employees
- 104
- IPO date
- Oct 2, 2020
Earnings Waterfall
C4 Therapeutics, Inc
The intrinsic value for
C4 Therapeutics, Inc (CCCC) under the Base Case is hidden USD.
Compared with the current market price of 3.005 USD, the stock appears hidden.